Hemorrhagic CVA in a Patient with Previous Infarcts: Acute Treatment
In a patient presenting with acute hemorrhagic stroke who has a history of prior ischemic infarcts, immediately discontinue all anticoagulants and antiplatelet agents, reverse any anticoagulation with appropriate agents (fresh frozen plasma or prothrombin complex concentrate plus vitamin K for warfarin; protamine for heparin), and manage blood pressure aggressively with a target systolic BP <140 mmHg within one hour 1, 2.
Immediate Management Priorities
Stop All Antithrombotic Therapy
- Discontinue anticoagulants and antiplatelets for at least 1-2 weeks during the acute period 1
- The history of prior ischemic strokes does NOT justify continuing antithrombotic therapy during acute hemorrhage—the immediate hemorrhage risk supersedes ischemic stroke prevention in this acute phase
Reverse Anticoagulation Urgently
For warfarin-associated ICH:
- Administer fresh frozen plasma or prothrombin complex concentrate PLUS vitamin K immediately 1
- Failure to achieve normal INR increases rebleeding risk 1
For heparin-associated ICH:
- Use protamine sulfate (Class I, Level B evidence) 1
- Dose depends on time from heparin cessation
Blood Pressure Management
- Target systolic BP <140 mmHg within one hour 3
- This aggressive early BP lowering is specific to hemorrhagic stroke and differs markedly from ischemic stroke management
Acute Care Setting
- Admit to organized stroke unit—this applies to both ischemic AND hemorrhagic stroke with strong evidence for improved outcomes 2
- Monitor closely for neurological deterioration and rebleeding
VTE Prophylaxis During Acute Phase
For nonambulatory patients with ICH:
- Start intermittent pneumatic compression (IPC) on day of diagnosis (Class I, Level B-R) 2
- Delay pharmacological prophylaxis (UFH or LMWH) until 24-48 hours post-ICH onset (Class IIb, Level C-LD) 2
- Do NOT use graduated compression stockings alone—they are not beneficial (Class III: No Benefit) 2
Critical Timing Consideration
The 24-48 hour delay for starting low-dose heparin prophylaxis optimizes the balance between preventing thrombosis and avoiding hemorrhage expansion 2. This is particularly important given your patient's dual risk profile.
When to Restart Antithrombotic Therapy
This is the most challenging decision in your clinical scenario. The patient has competing risks: recurrent ischemic stroke from prior infarcts versus recurrent ICH.
Risk Stratification for Restarting Therapy
Consider AGAINST restarting anticoagulation if:
- Lobar hemorrhage location (suggests cerebral amyloid angiopathy with highest recurrence risk) 1
- Elderly patient
- Poor overall neurological function
- Lower thromboembolic risk (e.g., atrial fibrillation without prior ischemic stroke) 1
May consider restarting if:
- Very high thromboembolic risk
- Deep (non-lobar) hemorrhage location
- Restart warfarin at 7-10 days after ICH onset for highest-risk patients (Class IIb, Level B) 1
Antiplatelet vs. Anticoagulation Decision
For patients with lower ischemic stroke risk and higher ICH recurrence risk (elderly with lobar ICH), an antiplatelet agent may be considered instead of anticoagulation 1. This represents a compromise between the two competing risks.
Key Pitfalls to Avoid
- Do NOT continue antithrombotics during acute ICH even with compelling ischemic stroke history—this is a common error
- Do NOT delay reversal of anticoagulation—every minute counts for preventing hematoma expansion
- Do NOT use heparin boluses if anticoagulation is eventually restarted—associated with increased bleeding 1
- Do NOT restart any antithrombotic therapy within 24 hours of the hemorrhage 1
Special Consideration: Hemorrhagic Transformation vs. Primary ICH
If imaging suggests hemorrhagic transformation within an ischemic infarct (rather than primary ICH), the natural history differs significantly. These hemorrhages are often asymptomatic, rarely progress, and continuing anticoagulation may be reasonable if there is compelling indication and the patient is not symptomatic from the hemorrhagic transformation (Class IIb, Level C) 1. Each case requires individual assessment based on hemorrhage size, symptoms, and anticoagulation indication.